Internal Medicine | Page 118 of 475 | Links Medicus Content Curation & Alerts in Medicine

Systematic Review: Prediction of good neurological outcome in comatose survivors of cardiac arrest.

7 Mar, 2022 | 00:40h | UTC

Prediction of good neurological outcome in comatose survivors of cardiac arrest: a systematic review – Intensive Care Medicine

Commentary on Twitter

Predicting good neuro outcome in comatose cardiac arrest survivors? Look at
? GCS motor 4/5
? normal NSE
? SSEP N20 wave amplitude > 4 μV or continuous EEG background without discharges
? no diffusion restriction in cortex or deep grey matter on MRI
SR https://t.co/ixkMvErdux pic.twitter.com/GjeuTLgDlb

— Intensive Care Medicine (@yourICM) March 4, 2022

Ten myths about albumin.

7 Mar, 2022 | 00:44h | UTC

Ten myths about albumin – Intensive Care Medicine (free for a limited period)

Commentary on Twitter

Albumin, 10 myths
1️⃣leaks into interstitium
2️⃣ ⬇️volume expansion vs artificial colloids
3️⃣ ⬇️AKI
4️⃣ sepsis: ⬆️survival
5️⃣ ⬆️diuretics effects
6️⃣RRT: ⬆️ fluid removal
7️⃣cirrhosis: ⬇️mortality
8️⃣TBI: ⬆️mortality
9️⃣correcting hypoalb ⬇️mortality
? ⬆️NaCl
? https://t.co/nGOHOLYRqY pic.twitter.com/YroygQNNUk

— Intensive Care Medicine (@yourICM) March 5, 2022

Review articles: Cutaneous manifestations of SARS-CoV-2 infection.

7 Mar, 2022 | 00:38h | UTC

Cutaneous Manifestations of SARS-CoV-2 Infection – American Journal of Clinical Dermatology

Common skin signs of COVID-19 in adults: An update – Cleveland Clinic Journal of Medicine

WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections.

7 Mar, 2022 | 00:09h | UTC

WSES/GAIS/WSIS/SIS-E/AAST global clinical pathways for patients with skin and soft tissue infections – World Journal of Emergency Surgery

Arterial blood gas analysis: as safe as we think? A multicentre historical cohort study.

7 Mar, 2022 | 00:00h | UTC

Arterial blood gas analysis: as safe as we think? A multicentre historical cohort study – ERJ Open

Hepatorenal Syndrome Type 1: From diagnosis ascertainment to goal-oriented pharmacologic therapy.

6 Mar, 2022 | 23:47h | UTC

Hepatorenal Syndrome Type 1: From Diagnosis Ascertainment to Goal-Oriented Pharmacologic Therapy – Kidney360

Viewpoint | Looking back on the history of patient safety: an opportunity to reflect and ponder future challenges.

6 Mar, 2022 | 23:51h | UTC

Looking back on the history of patient safety: an opportunity to reflect and ponder future challenges – BMJ Quality & Safety

Systematic Review: Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding.

6 Mar, 2022 | 23:41h | UTC

Proton pump inhibitor treatment initiated prior to endoscopic diagnosis in upper gastrointestinal bleeding – Cochrane Library

Commentary: Pre-Endoscopic Proton Pump Inhibitor Use May Decrease Risk for Endoscopic Hemostatic Treatment – Gastroenterology Advisor

Distribution of delirium motor subtypes in the intensive care unit: a systematic scoping review.

6 Mar, 2022 | 23:38h | UTC

Distribution of delirium motor subtypes in the intensive care unit: a systematic scoping review – Critical Care

RCT: Preliminary trial suggests neostigmine may improve intra-abdominal hypertension and increase defecation in patients with acute pancreatitis.

6 Mar, 2022 | 23:39h | UTC

Randomized controlled trial: neostigmine for intra-abdominal hypertension in acute pancreatitis – Critical Care

M-A: Bariatric surgery and cardiovascular disease.

6 Mar, 2022 | 23:34h | UTC

Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis – European Heart Journal

[Preprint] RECOVERY trial shows Baricitinib reduces deaths in patients hospitalized with COVID-19.

4 Mar, 2022 | 10:09h | UTC

News Release: RECOVERY trial shows Baricitinib reduces deaths in patients hospitalised with COVID-19 – University of Oxford

Original study: Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis – medRxiv

Commentaries:

Arthritis drug reduces mortality in severe COVID-19, huge clinical trial finds – Science

Covid-19: Anti-inflammatory treatment baricitinib reduces deaths in patients admitted to hospital, finds trial – The BMJ

Another life-saving Covid drug identified – BBC

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

RCT: Baricitinib reduced mortality in hospitalized adults with COVID-19.

Randomized trial: Baricitinib plus remdesivir reduce recovery time in patients with COVID-19

Commentary from the author on Twitter (thread – click for more)

RECOVERY pre-print: Baricitinib

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis https://t.co/g0cNjaBzEL

— Martin Landray (@MartinLandray) March 3, 2022

Updated WHO guidance conditionally recommends Molnupiravir for patients with non-severe covid-19 at highest risk of hospitalization.

4 Mar, 2022 | 09:57h | UTC

BMJ News Release: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ

WHO News Release: WHO updates its treatment guidelines to include molnupiravir

See updated guidance: A living WHO guideline on drugs for covid-19 – BMJ

Editorial (just published): Molnupiravir’s authorisation was premature – The BMJ

RCT: Molnupiravir reduced the risk of hospitalization or death in at-risk (i.e., obesity, over 60 years, etc.) unvaccinated adults with Covid-19.

Merck’s COVID pill loses its luster: what that means for the pandemic – “Molnupiravir was initially heralded by public-health officials as a game-changer for COVID-19, but full clinical-trial data showed lower-than-expected efficacy”.

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

M-A: Efficacy of covid-19 vaccines in immunocompromised patients.

4 Mar, 2022 | 10:01h | UTC

Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis – The BMJ

News Release: Study suggests additional covid-19 vaccine doses for immunocompromised patients – BMJ Newsroom

Commentary on Twitter

NEW RESEARCH: Additional doses of covid-19 vaccine are recommended for immunocompromised patients, especially for organ transplant recipients who are least able to make antibodies to fight off coronavirus, suggests new research https://t.co/l2IWfSb0zd @sundar__raghav

— The BMJ (@bmj_latest) March 3, 2022

Viewpoint: Understanding and communicating uncertainty in achieving diagnostic excellence.

4 Mar, 2022 | 09:56h | UTC

Understanding and Communicating Uncertainty in Achieving Diagnostic Excellence – JAMA (free for a limited period)

Systematic Review: Arthroscopic surgery provides little or no clinically important benefit for patients with degenerative knee disease.

4 Mar, 2022 | 09:53h | UTC

Arthroscopic surgery for degenerative knee disease (osteoarthritis including degenerative meniscal tears) – Cochrane Library

Summary: Arthroscopic surgery for degenerative knee disease – Cochrane Library

G uideline: Arthroscopic Meniscal Surgery

Arthroscopic surgery for degenerative knee arthritis and meniscal tears: a clinical practice guideline

Randomized Trial: Early Surgery vs Physical Therapy on Knee Function Among Patients With Nonobstructive Meniscal Tears

Study: Adverse Outcomes After Arthroscopic Partial Meniscectomy

A guideline for the outpatient management of glycemic control in people with cancer.

4 Mar, 2022 | 08:56h | UTC

A guideline for the outpatient management of glycaemic control in people with cancer – Diabetic Medicine

Randomized Diagnostic Study: home blood pressure measurements correlate better with 24-h ambulatory monitoring measurements compared to clinic, and kiosk measurements.

4 Mar, 2022 | 09:41h | UTC

Clinic, Home, and Kiosk Blood Pressure Measurements for Diagnosing Hypertension: a Randomized Diagnostic Study – Journal of General Internal Medicine

Commentary: Home blood pressure monitoring may provide the basis for accurate diagnoses of hypertension – Kaiser Permanente

Risk of cancer with angiotensin-receptor blockers increases with cumulative exposure: Meta-regression analysis of randomized trials.

4 Mar, 2022 | 08:49h | UTC

Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials – PLOS One

Commentary: ARBs and Cancer Risk: New Meta-Analysis Raises Questions Again – Medscape (free registration required)

Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts.

4 Mar, 2022 | 08:45h | UTC

Daily steps and all-cause mortality: a meta-analysis of 15 international cohorts – The Lancet Public Health

Commentaries:

Meta-analysis of 15 studies reports new findings on how many daily walking steps needed for longevity benefit – University of Massachusetts Amherst

Living a long life is a multi-step process – The Lancet Public Health

Podcast: Obesity medicine pearls.

4 Mar, 2022 | 08:43h | UTC

#324: Obesity Medicine FAQ with Dr. Fatima Cody Stanford – The Curbsiders

Diagnosis, management and therapeutic strategies for congenital long QT syndrome.

4 Mar, 2022 | 08:39h | UTC

Diagnosis, management and therapeutic strategies for congenital long QT syndrome – Heart

Commentary on Twitter

Excellent review on congential long QT syndrome:

Diagnosis, management and therapeutic strategies for congenital long QT syndromehttps://t.co/FECINw9k7g pic.twitter.com/O4s5GwKK3O

— Heart_BMJ (@Heart_BMJ) June 19, 2021